Thymalin

Thymalin is a preparation of peptides from the thymus gland, similar to Thymosin Alpha-1 but less purified. It has been used in Russia and Eastern Europe for immune modulation. Limited clinical data in Western literature.

PubMed results: 234 · Human studies: 156 · Animal studies: 232

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Intramuscular — standard range 10 mg daily, Once daily for short courses (commonly 5–10 consecutive days). Russian clinical research and approved-product use commonly studied intramuscular courses of about 10 mg daily for 5–10 days (e.g., published COVID-19 adjunct study used 10 mg IM daily for 10 days). Historical immune-modulation protocols often repeat short courses seasonally or a few times per year. Not FDA-approved; Western controlled PK/dose-standardization data remain limited.

Not established as a single-entity PK value (low confidence)

Thymalin is a multi-peptide thymic extract (polypeptide complex), not a single defined molecular entity, so a classic single-compound plasma half-life is not well published in Western literature. Related purified thymic peptides historically show very short systemic half-lives, but that should not be extrapolated as a measured Thymalin value.

• Immune modulation (thymic peptide preparation) (Limited): Thymalin is a thymus-derived peptide preparation studied primarily in Russian and Eastern European settings for effects on immune cell function and recovery of immune parameters after stress or illness; Western peer-reviewed clinical evidence remains sparse.
• T-cell related immune research interest (Theoretical): As a thymic extract-type preparation related conceptually to thymic peptides, research interest focuses on supporting thymic-axis signaling and adaptive immune regulation rather than a single well-defined receptor mechanism in Western literature.

• Limited adverse-event documentation in Western literature — Mild, Not established. Published Western clinical safety datasets for Thymalin are limited; injection-site discomfort is the most plausible local effect based on subcutaneous peptide administration generally, but robust frequency estimates are not established.
• Injection site reactions — Mild, Anecdotal. Where parenteral use is described, local reactions such as mild pain or erythema are consistent with peptide injection practice; systematic adverse-event rates are poorly characterized outside regional literature.

• Hypersensitivity to thymic preparations (Theoretical / Preclinical): As a multi-peptide thymic preparation (less purified than single-agent thymosin analogs), hypersensitivity or intolerance to components of thymus-derived products is a standard theoretical exclusion.
• Uncontrolled autoimmune disease (theoretical) (Theoretical / Preclinical): Immune-modulating thymic peptides raise theoretical concern about altering immune set-points in active autoimmunity; clinical decision frameworks often treat this as a caution given limited controlled data.

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water